Class:

Aurora A kinase inhibitors

Adpated from Niu, H et al. Scientific rationale supporting the clinical development strategy for the investigational Aurora A kinase inhibitor alisertib in cancer. Front Oncol. 2015 Aug; 5:189.  doi: 10.3389/fonc.2015.00189.

All content on this site is intended for healthcare professionals only. If you are a patient or carer, please visit the Lymphoma Coalition.